MedDataX Logo

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

NCT ID: NCT06640933

Last Updated: 2025-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-16

Study Completion Date

2025-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, researchers will learn how the body processes new tablet forms of BIIB091 when taken with and without food. One new form of BIIB091 is an "extended release" tablet, also known as "ER." This form helps release BIIB091 slowly and consistently, helping to keep steady drug levels in the body for longer. The other new form is a "gastro-retentive" tablet, also known as "GR." This form has a special coating that swells and allows BIIB091 to stay in the stomach longer. For both GR and ER tablets, there are also "slow" and "fast" forms that change how quickly BIIB091 is released into the body. But, eating food with these tablets may affect how much BIIB091 is in the body.

The main objective of this study is to learn how 2 new forms of BIIB091, which are released into the body at different rates, are processed in the body. Researchers also want to learn how these new forms compare to the "immediate release" tablet, also known as "IR". This form delivers BIIB091 immediately into the body.

The main question researchers want to answer in this study is:

* How does the body process different tablet forms of BIIB091 with or without food?

Researchers will also learn more about:

* How the body processes the 2 new tablet forms of BIIB091 with food compared to the IR tablet form with food
* How the body processes the ER tablet form of BIIB091 with food compared to without food
* Any medical problems the participants have during the study
* Any changes in the participants' overall health during the study

This study will be done as follows:

* Participants will be screened to check if they can join the study. The screening period will be up to 22 days, after which eligible participants will check into their study research center.
* Participants will be randomly assigned to 1 of 6 groups. In each group, the participants will take the below tablet forms, but in different orders:

* Immediate-Release (IR)
* Gastro-Retentive slow (GR-slow)
* Gastro-Retentive fast (GR-fast)
* Extended-Release slow (ER-slow)
* Extended-Release fast (ER-fast)
* ER-slow, without food
* Each period includes the participant taking a single dose of what they were assigned to on the first day. There will be 3 days of no dosing in each period. The participant will then move to the next tablet form assigned. This will continue until each participant has taken a single dose of each of the 6 tablet forms.
* Participants will remain at their study research center for 25 days for the treatment periods. Afterwards, there will be follow-up visit 11 to 14 days after each participant's last dose. Each participant will be in the study for up to 57 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to characterize the pharmacokinetics (PK) of BIIB091 after a single oral dose of different BIIB091 formulations with or without food conditions in healthy participants.

The secondary objectives of this study are: to compare the exposure of BIIB091 after a single oral dose of 4 new BIIB091 formulations (GR-fast, GR-slow, ER-fast, ER-slow) with a moderate-fat meal versus a single oral dose of BIIB091 IR tablets with a moderate-fat meal in healthy participants; to compare the exposure of BIIB091 after a single oral dose of BIIB091 ER-slow formulation with a moderate-fat meal versus under fasting conditions in healthy participants; to evaluate the safety and tolerability of BIIB091 after a single oral dose of different BIIB091 formulations with or without food conditions in healthy participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BIIB091 IR

Participants will receive BIIB091 IR tablets on Day 1 of its respective period, with food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

BIIB091 GR-slow

Participants will receive BIIB091 GR-slow tablets on Day 1 of its respective period, with food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

BIIB091 GR-fast

Participants will receive BIIB091 GR-fast tablets on Day 1 of its respective period, with food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

BIIB091 ER-slow

Participants will receive BIIB091 ER-slow tablets on Day 1 of its respective period, with food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

BIIB091 ER-fast

Participants will receive BIIB091 ER-fast tablets on Day 1 of its respective period, with food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

BIIB091 ER-slow Fasted

Participants will receive BIIB091 ER-slow tablets on Day 1 of its respective period, without food.

Group Type EXPERIMENTAL

BIIB091

Intervention Type DRUG

Administered as specified in the treatment arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIIB091

Administered as specified in the treatment arm.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a body mass index (BMI) of 18 to 32 kilograms per meter square (kg/m\^2), inclusive, and a total body weight \>50 kg, Screening and Day -1.
* Negative polymerase chain reaction (PCR) test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in (Day -1).
* For Japanese participants:

* Have biological parents and grandparents of Japanese origin.
* If living outside of Japan for more than 5 years, must not have significantly modified diet since leaving Japan.

Exclusion Criteria

* History of any clinically significant cardiac, endocrine,gastrointestinal (GI), hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease or other major disease, as determined by the Investigator.
* History of torsades de pointes or additional risk factors for torsades de pointes.
* Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Biogen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

PPD Las Vegas Research Unit

Las Vegas, Nevada, United States

Site Status

PPD Clinical Research Unit

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

257HV106

Identifier Type: -

Identifier Source: org_study_id